HUMAN monocytes, preincubated with IFN-γ, respond to IL-4 by a cGMP increase through activation of an inducible NO synthase. Here, IL-4 was found to induce an accumulation of cGMP (1–3 min) and cAMP (20–25 min) in unstimulated monocytes. This was impaired with NOS inhibitors, but also with EGTA and calcium/calmodulin inhibitors. These results suggest that (1) IL-4 may stimulate different NOS isoforms in resting and IFN-γ activated monocytes, and (2) cAMP accumulation may be partially dependent on the NO pathway. By RT-PCR, a type II constitutive NOS mRNA was detected in U937 monocytic cells. IL-4 also increased the [Ca²⁺]i in these cells. Different NOS may thus be expressed in monocytic cells depending on their differentiation and the signals they receive.

Key words: [Ca²⁺]i, cAMP, cGMP, Human monocytes, IL-4, NO synthase.

IL-4 induces cAMP and cGMP in human monocytic cells

B. Dugas,1 N. Paul-Eugene,2 K. Yamaoka,4 C. Amirand,3 C. Damais2 and J. P. Kolb4

1URA CNRS 625, Hôtel Pitié-Salpêtrière, 75013 Paris; 2INSERM U313, Centre Bio Médical des Cordeliers, 75006 Paris; 3URA CNRS 198, and
4INSERM U365, Institut Curie, 75005 Paris, France

CA Corresponding Author

Introduction

Interleukin-4 (IL-4) is a 20 kDa glycoprotein, produced by activated T lymphocytes (Th2), mast cells, basophils and other cell types, which displays a broad spectrum of biological activity on haematopoietic cells.1 On monocytes/macrophages, IL-4 enhances the expression of MHC class II antigens, adhesion molecules of the LFA-1 (leucocyte functional antigen) family2 and CD23.3 In contrast, IL-4 down-regulates the expression of FcγRI (CD64) and FcγRII (CD32) and inhibits the induction of FcγRIII (CD16) by IFN-γ4 or TGF-β.5 IL-4 also down-regulates the expression of CD14 on monocytes.5 IL-4 acts as an anti-inflammatory mediator by decreasing the release of IL-1, TNF-α, IL-6, IL-8 and prostaglandin E2 by human monocytes and by reducing their capacity to produce reactive oxygen species.7–12 IL-4 also induces the secretion of G- and M-CSF by monocytes13 and triggers their differentiation into macrophage-like cells type in vitro.

The binding component of the IL-4 receptor belongs to the family of haemapoietin receptors14,15 and is associated, at least in some cell types, to the γ chain previously reported for the IL-2 receptor.16–22 The importance of protein tyrosine phosphorylation in IL-4 signalling is now well recognized23–28 and recently, the Jak329 and Lsk30 have been identified as the major tyrosine kinases involved. Several transcription factors are selectively activated through IL-4-induced tyrosine phosphorylation.31,32

We recently described that IL-4 induced an accumulation of cGMP in monocytes of certain donors, which was greatly enhanced by pre-incubation with IFN-γ and was dependent on the l-arginine-dependent pathway of nitric oxide synthase (NOS) activation, since it was markedly reduced in the presence of NOS inhibitors.33 We also reported that IL-4 displayed a biphasic effect on the capacity of cultured monocytes to release nitrite in their supernatants.34 In the present work, we have further analysed the effect of IL-4 on the production by monocytic cells of the cyclic nucleotides cAMP and cGMP.

Materials and Methods

Reagents: Recombinant human IL-4 obtained from Escherichia coli (specific activity, 1 × 10⁷ U/mg, 1 U = 1 ng) was purchased from Immugenex (Los Angeles, CA, USA). Isobutyl methyl xanthine (IBMX), EGTA (ethylene glycol-bis(β-aminoethyl ether) N,N,N',N'-tetraacetic acid) and the two inhibitors of calmodulin, calmidazolium and W-7, were purchased from Sigma (Saint Louis, MO, USA). N⁵-mono-methyl-l-arginine (L-NMMA) and N⁵-nitro-l-arginine (L-NA), two N-guanido-substituted analogues of l-arginine, competitive inhibitors of NO synthase, were purchased from Calbiochem and Sigma, respectively. The neutralizing anti-IL-4 mAb was from Immunotech (Luminy, France).

Isolation of human monocytes: Blood samples were obtained from cytapheresis of normal donors, as residues of platelet preparations, through the courtesy of the blood transfusion centres of Créteil and Hôtel-Dieu. Blood donors
IL-4 triggers cAMP and cGMP in monocytes.

Peripheral blood mononuclear cells (PBMC) were purified as previously described. Briefly, blood samples were centrifuged at 200 × g for 10 min in order to eliminate the residual contaminating platelets. Then, samples were diluted in RPMI 1640 medium (Bioproduct, Les Ulis, France) and PBMC were harvested after a 20 min centrifugation at 800 × g on Ficoll-Hypaque (Pharmacia, Uppsala, Sweden) gradient. Peripheral blood mononuclear cell populations were obtained by incubation of PBMC (1 × 10^7 cells/ml) in Petri dishes (Nunc, Rocksville, Denmark) for 1 h at 37°C in RPMI 1640 medium supplemented with 10% FCS (Gibco, Paisley, UK). Monocytes were harvested by scraping the plates with a rubber policeman after addition of cold phosphate-buffered saline solution (PBS) containing 1 mM EDTA. Cell preparations were composed of more than 95% viable monocytes as assessed by the Trypan blue exclusion method and nonspecific esterase staining. Other contaminating cells were lymphocytes and granulocytes which never exceeded 5% of the total cell number, whereas platelet contamination was undetectable.

**Monocytic cell line**: U937 promonocytic cells were maintained in RPMI-1640 medium (Gibco, Paisley, Scotland) supplemented with 5% FCS (Gibco: LPS levels <0.2 ng/ml), 2 mM L-glutamine, 1 mM pyruvate, penicillin 100 U/ml, streptomycin 100 μg/ml (Flow Laboratories, Rockville, MD) in a 5% CO₂ humidified atmosphere at 37°C. For experiments, the cells were collected, washed and counted with a Coulter counter ZM, equipped with a Coultronic 256 channelizer (Coultronics, Margency, France).

**Determination of cAMP and cGMP**: For measuring the cytoplasmic cGMP and cAMP levels in whole cells, monocytes were resuspended at 7 × 10^6/ml in RPMI 1640 medium supplemented with 200 μM of the phosphodiesterase inhibitor IBMX and incubated at 37°C for 15 min. After the incubation period, 1 × 10^6 cells (135 μl) were distributed in duplicate or triplicate samples in Eppendorf microtubes. Fifteen μl of the different ligands were added for various periods of incubation at 37°C in a water bath. The reactions were stopped by addition of 25 μl of 35% perchloric acid (PCA) and immediate cooling on ice. The tubes were allowed to stand at 0°C for 15 min, then spun at 3000 × g for 15 min. The pellets were discarded and the supernatants neutralized with KOH. The KClO₄ precipitates were removed by a second centrifugation at 3000 × g for 15 min at 4°C. The neutralized supernatants were kept frozen at −70°C until cGMP and cAMP determinations. After acetylation of the samples, the concentrations of cGMP and cAMP were determined by specific radioimmunoassays, according to the specifications of the manufacturers (kits from Amersham France, Les Ulis or from NEN, Dupont, Dreieich, Germany). The significance of the results was analysed by the Student's t-test, adapted for small samples.

**Identification of constitutive NO synthase in monocytes by reverse transcription-polymerase chain reaction**: Total RNA samples were extracted from monocytes and U937 cells by a modification of the technique of MacDonald et al. Briefly, cells were washed twice in ice-cold PBS then resuspended in 1.5 ml of 5 M guanidinium thiocyanate (Fluka, Buchs, Switzerland). After sonication for 20 s in a Vibra Cell sonifier (Bioblock Scientific, Illkirch, France) at 40% maximal power, the cell lysates were layered on 1.5 ml cushions of 5.7 M CsCl dispersed in poly-carbonate tubes and centrifuged at 20000 × g for 3 h at 20°C in the TLA 100.3 rotor of a TL 100 ultracentrifuge (Beckman Instruments). After two washings with formamide/ethanol (30/70 v/v), the pellet was dried and resuspended in 200 μl of TE buffer (Tris 10 mM, EDTA 1 mM). After addition of 0.1 vol of 3 M sodium acetate, the samples were mixed with 2 vol of absolute ethanol and then placed at −70°C overnight to precipitate total RNA. Sedimentation at 13200 × g for 30 min at 4°C was performed and the resulting total RNA pellet was dried, resuspended in diethyl pyrocarbonate (DEPC)-treated deionized water and its concentration was estimated by spectrophotometry. Total RNA (1–2 μg) from monocytes and U937 cells was reverse transcribed using random hexanucleotides as primers (First-strand cDNA synthesis kit, Amersham France, Les Ulis, France). The cDNA generated was then amplified by the polymerase chain reaction. After an initial denaturation step at 94°C, 30 PCR cycles were performed as follows: 25 s at 95°C, 1 min at 57°C, 1 min at 72°C, followed by a final extension step of 5 min at 72°C. The following oligonucleotide primers, based on the human endothelial cells cNOS cDNA sequence, were used to amplify the monocytes and U937 NOS cDNA: forward, 5'-GCA TCA CCT ATG ACA CCG TCA GCG-3'; reverse, 5'-AGC TCG CTC TCC CTA AGC TGG TAG G-3'. These primers define a fragment of 277 bp. Oligonucleotides were synthesized by Genset (Paris, France), except for control primers for human β-actin which were obtained from Stratagene (La Jolla, CA, USA). Products of the reverse tran-
Determination of $[\text{Ca}^{2+}]_i$ Cells were loaded with 10 μM of the fluorescent probe Fluo 3-acetoxymethylester (Fluo 3-AM) for 1 h at 37°C; the cells were washed and resuspended in RPMI-1640 medium, without phenol red, containing 10 mM HEPES. Fluorescence intensity (in arbitrary units) of Fluo-3 AM-loaded U937 cells was recorded as a function of the wavelength between 500 and 600 nm (maximum emission of Fluo-3/Ca complex: 535 nm), as described previously. The free calcium concentration $[\text{Ca}^{2+}]_i$ in the cells is related to the fluorescence intensity ($F$) by the following equation:

$$[\text{Ca}^{2+}]_i = K_d \times \frac{(F - F_{\min})}{(F_{\max} - F)}$$

where $F_{\max}$ is determined by measuring fluorescence after the cells are lysed in 0.1% Triton X-100 (Sigma), whereas $F_{\min}$ is determined after addition of 10 mM EGTA. The effective constant $K_d$ of Fluo-3 in solution has been reported to be 400 nM. Fluo-3 is analysed in the visible range, thus the problems associated with the use of UV light are avoided. In addition, the large increase of the fluorescence emission by binding of Ca$^{2+}$ to Fluo-3 allows a great sensitivity for measuring small variations in calcium concentration. However, upon binding of Ca$^{2+}$, there are no shifts in its excitation or emission spectrum, which makes Fluo-3 non-ratioable and therefore will compromise the accuracy of absolute $[\text{Ca}^{2+}]_i$ determinations. For these reasons, our data have been presented as fluorescence intensities.

Results

IL-4 stimulates a biphasic cyclic AMP accumulation in human monocytes: Incubation of freshly isolated monocytes with IL-4 was found to result in a delayed accumulation of cAMP, starting at 10 - 15 min and peaking about 20 - 25 min after addition of the cytokine. For some donors, a transient peak of cAMP was also observed after 1 min of stimulation, as shown in the typical response presented in Fig. 1. After a phase of plateau until 30 min, a progressive decrease occurred and a return to the basal value was achieved around 1 h after the beginning of the stimulation (not shown). The increase in cAMP content over background was usually in the range 50 - 300% ($n = 11$). This late increase in cAMP was dependent on the concentration of IL-4, as presented in Fig. 2. When the experiments were performed in the presence of 10 μM indomethacin, a cyclooxygenase inhibitor, the IL-4-induced cAMP response was not significantly affected, indicating that the increase in cAMP was not secondary to a release of prostaglandins (not shown).

IL-4 stimulates cyclic GMP accumulation in human monocytes: The kinetics of IL-4 driven cAMP and cGMP accumulation were compared in unstimulated monocyte preparations from the same donors and typical results are presented in Fig. 3. It was regularly observed that the peak of cGMP accumulation (between 3 and 10 min) preceded that of late cAMP accumulation. For eleven donors tested, the range of cGMP accumu-
IL-4 triggers cAMP and cGMP in monocytes

Inhibitors of the nitric oxide synthase pathway impair the IL-4-driven cyclic nucleotides accumulation in resting monocytes: The heterodimeric soluble guanylyl cyclases, which convert GTP into cGMP, are activated by NO-generating compounds through interactions of the NO radical with their haeminic prosthetic groups. In order to test whether the observed accumulation of cGMP in response to IL-4 was due to a generation of NO, two classical inhibitors of the L-arginine pathway of NO synthase activation were added to unstimulated monocytes prior to their incubation with IL-4: L-NMMA, and nitro-L-arginine which, at variance with L-NMMA, does not compete with L-arginine for its transport into the cells. As seen in Table 1, the IL-4-driven cGMP accumulation was almost totally abolished in the presence of these competitive inhibitors of L-arginine for the NOS. Interestingly, IL-4-driven cAMP accumulation was also markedly affected with L-NMMA as shown in Fig. 4, suggesting that both cAMP and cGMP production were related to the NO pathway.

TABLE 1. IL-4-driven cyclic nucleotide accumulation in human monocytes is inhibited with a specific neutralizing anti-IL-4 antibody

|          | cAMP (fmol/10^6 cells) | cGMP (fmol/10^6 cells) |
|----------|------------------------|------------------------|
| Medium   | 480 ± 50               | 410 ± 110              |
| IL-4     | 1500 ± 190             | 1220 ± 130             |
| IL-4 + anti-IL-4 | 510 ± 70         | 510 ± 80               |

Monocytes were incubated for 3 min (cGMP) or 20 min (cAMP) with medium, IL-4 (10 ng/ml), or IL-4 and anti-IL-4 mAb (20 μg/ml). The reactions were then stopped and cells extracts were determined for their content in cAMP and cGMP as described in Materials and Methods. Results are the mean ± S.E.M. of triplicate samples from one representative experiment out of two.

Effect of calcium chelator and calmodulin inhibitors on IL-4 driven cGMP accumulation: Several NOS isoforms have been described, which differ in their sensitivity to calcium for the stimulation of their catalytic activity. Various inhibitors of the Ca/CaM complex were thus tested.

***FIG. 3. Kinetics of IL-4-driven cGMP accumulation in human monocytes. Monocytes were stimulated with IL-4 (10 ng/ml) for the times indicated and cGMP concentrations were determined by RIA on perchloric extracts, as described by Materials and Methods. Data are mean ± S.E.M. of triplicate samples from one experiment representative of nine where a significant cGMP response could be detected.***

**FIG. 4. Effect of L-NMMA on IL-4-induced cAMP accumulation in human monocytes. Monocytes were preincubated or not with L-NMMA (1 mM) for 30 min at 37°C, then stimulated for 20 min with medium or IL-4 (10 ng/ml). Results are mean ± S.E.M. of triplicate samples from one representative experiment out of seven. *p < 0.01; **p < 0.05.***

Mediators of Inflammation · Vol 4 · 1995 · 301
and, as seen in Table 3, the IL-4-stimulated cGMP increase was greatly reduced either in the presence of the calcium chelator EGTA or of the calmodulin inhibitor W7, both reagents being ineffective alone at the concentrations tested. Similar results were obtained with calmidazolium, another inhibitor of the Ca/CaM complex (not shown). These results therefore suggested that the NOS involved may be different from the inducible type II NOS detected in IFN-γ-preincubated monocytes and could be activated through variations in intracytoplasmic calcium concentration and therefore be related to the constitutive NOS isoforms.

**IL-4 stimulates an increase in intracytoplasmic free calcium \([Ca^{2+}]_i\) in unstimulated monocytic cells:** Inasmuch as cNOS are regulated via transient calcium increases, we measured the effects of IL-4 on the \([Ca^{2+}]_i\) in a monocytic cell line, U937 cells, which behave like blood monocytes with regard to cyclic nucleotide accumulation in response to IL-4. As seen in Fig. 5, addition of IL-4 to Fluo-3-loaded resting U937 cells resulted within 20s in a marked increase in \([Ca^{2+}]_i\). Although Fluo-3 is not ratio able, an approximate calculation gives a value of 78 nM for the \([Ca^{2+}]_i\), in the resting state which increased to about 1070 nM after IL-4 administration. These results were confirmed by micro-spectrofluorometric techniques at the single cell level; high increases in fluorescence intensity were recorded following IL-4 addition to U937 cells, although we observed that the response of individual cells was heterogeneous, some cells being unresponsive to IL-4 stimulation (data not shown). These results demonstrate that IL-4 is able to elicit an increase in \([Ca^{2+}]_i\) in monocyte cells, a prerequisite for the activation of cNOS in these cells. Indeed, the catalytic activity of the constitutive type I and III cNOS are regulated by the Ca/CaM complex, through an increase in the intracellular concentration of free calcium \([Ca^{2+}]_i\), evoked by specific hormones or neurotransmitters. When calcium ionophores such as ionomycin and A23187 were added to monocytes, however, no increase in cGMP over the basal concentration was detected, nor any significant release of nitrite in the supernatant of these cells; the same negative results were obtained when monocytes or U937 cells were incubated in the presence of thapsigargin, an inhibitor of the endoplasmic reticulum calcium ATPase, which constitutes another way to raise the intracytoplasmic \([Ca^{2+}]_i\). An increase in \([Ca^{2+}]_i\) is therefore not sufficient, alone, to trigger cGMP accumulation by monocyte cells.

**Detection by RT-PCR of type III cNOS mRNA in human monocytic cells:** Total RNA from human monocytes and U937 cells were reverse transcribed and amplified by the polymerase chain reaction, using primers specific for the constitutive endothelial human NO synthase. As seen in Fig. 6, a fragment of 277 bp was readily detected in U937 cells, which corresponds to the size expected from the sequence of the endothelial NO synthase. Although much weaker than that of U937 cells, this band was also observed with monocytes (not shown). Treatment of U937 cells with either IL-4, or IL-4 and anti-C23 mAb, or IFN-γ, did not modify the expression of cNOS.

**Discussion**

We have previously observed that, for a fraction of the donors tested, IL-4 induced a cGMP increase in unstimulated monocytes; a much higher response was detected when monocytes were preincubated with IFN-γ; this was inhibited in the presence of l-NMMA and was not affected by calcium chelation, suggesting the activation of
IL-4 triggers cAMP and cGMP in monocytes

An iNOS. In addition, IL-4 induced a slight production of nitrite by monocytes, which was potentiated by IFN-γ and inhibited by L-NMMA. These results suggested that the sequential exposure of monocytes to IFN-γ and IL-4 elicited the release of NO from L-arginine, which in turn was able to stimulate soluble guanylate cyclase. We have also reported that IL-4 induced an heterogeneous and late accumulation of nitrite in monocyte supernatants. In the present work, we show that IL-4 induces cAMP and cGMP generation in unstimulated human monocytes. A rather large heterogeneity in the response of the different individuals was observed, which may be explained by the fact that, except for the absence of HIV or hepatitis infection and of allergy, the immunological status of these donors was largely unknown. One cannot exclude the possibility that some of these volunteers were primed otherwise which may explain the variation in the response observed and the biphasic cAMP response which was detected for some of them. We have no direct explanation for this early cAMP increase; tentatively, one may speculate that it could be achieved through a cross stimulation of β2 receptors, inasmuch as we have previously demonstrated a functional interplay between the response of monocytes to IL-4 and to β2 agonists. Hart et al did not detect significant cAMP accumulation in elutriation-enriched monocytes stimulated by IL-4 or IL-4 plus LPS; however, their experiments were performed with low concentration of IL-4 (1 ng/ml), that, in our hands too, only triggered a slight cAMP increase, whereas higher IL-4 concentrations stimulated significant increases in both cyclic nucleotides.

The IL-4 receptor binding unit and its γ chain-associated component do not belong to the family of receptors with seven spanning domains, capable of interacting with G proteins and leading to the activation of adenylate cyclase (AC). Furthermore, whether the associated γ chain has been detected in lymphoid cells, it appears to be absent in monocytic cells, as revealed by RT-PCR. The late accumulation of cAMP suggested therefore an indirect mechanism of action of IL-4. Activation of AC via the induction of prostaglandin by IL-4 was ruled out, since the IL-4-driven cAMP accumulation was not significantly affected in the presence of indomethacin, an inhibitor of cyclooxygenase. Alternatively, the observed IL-4-induced cAMP accumulation could result from AC stimulation through the activation of PKC or of the calcium/calmodulin complex.

The role of protein kinase C (PKC) and cyclic nucleotides in IL-4 signalling is controversial. Arruda and Ho presented evidence that, in human monocytes, IL-4 signalling involved PKC translocation to a nuclear fraction, without parallel increase in [Ca²⁺], suggesting a possible role for phosphatidylinositol hydrolysis in this process; the same group has shown recently that IL-4 signalling in monocytes and U937 cells involves the activation of a phosphatidylinositol-specific phospholipase C (PC-PLC), but not of phosphatidylinositol 4,5-bisphosphate phospholipase C (PIP₂-PLC), PLA₂, PLD nor sphingomyelinase. In contrast, our data clearly indicate that IL-4 stimulates an increase in [Ca²⁺] in human promonocytic U937 cells, despite the usual considerable variation which was observed when the response of individual cells was measured. The fluorescent probe we used, Fluo-3 is slightly more convenient for detecting small variations in calcium concentration than Fura-2, used by Ho et al., but this is not sufficient to explain the reasons for this discrepancy. Alternatively there may exist differences between various sub-clones of U937 cells. Our kinetic studies indicate that the late peak of cAMP generation is preceded by an increase in cGMP. At variance with the results observed with rodent monocytes, where a 30 – 100 fold difference between cAMP and cGMP levels has been reported, our data indicate that the basal concentration of cGMP is roughly of the same order of magnitude as that of cGMP, which is more in agreement with the results obtained for human monocytes by Li et al. The differential kinetics of the cGMP and cAMP increases suggested a possible link between the accumulation of these two cyclic nucleotides. Indeed, both cGMP and
cAMP accumulation were suppressed by L-NMMA and nitro-l-arginine, two inhibitors of the NO synthase (NOS). Nitric oxide (NO), which has been identified in recent years as a pleiotropic mediator, is a short-lived radical generated by oxidation of the guanidino group of l-arginine by constitutive or inducible NO synthases. Soluble guanylate cyclase is activated by NO through interaction with its haem group, which leads to increased cGMP concentration. The subsequent cAMP increase we observed following addition of IL-4 to monocytes could then result from an interplay in the cyclic nucleotide phosphodiesterases (CN-PDE) network. Noteworthy, Li et al. have reported that IL-4 and IFN-γ synergistically elicited a marked increase in cAMP phosphodiesterase activity in human monocytes. We have also observed that IL-4 stimulated CN-PDE activity in resting monocytes (not shown). This high CN-PDE activity may help explain the decrease in cAMP and cGMP levels observed in time, despite the presence of IBMX, a nonspecific inhibitor of the various CN-PDE iso-enzymes. Whereas Endres et al. observed that CN-PDE inhibitors such as IBMX suppressed the LPS-induced TNF-α production by human mononuclear cells (PBMC) through the accumulation of cAMP, Paul-Eugene et al. recently reported that low concentrations of IBMX (10 μM) potentiated the IL-4-driven IgE production and sCD23 release by PBMC.

The cGMP increase might activate the cGMP-inhibitable cAMP-specific phosphodiesterase, (type III CN-PDE), that would result in subsequent cAMP accumulation, independent of the activation of adenyl cyclase and might explain the delayed phase of cAMP increase. Experiments are in progress to study this mechanism and preliminary results suggest that both chemical NO donators and permeant cGMP analogues, such as Sp-cGMP, are able to trigger cAMP accumulation in monocytes.

Both cGMP and cAMP increases were affected in the presence of EGTA, a calcium chelator, and of W-7 or calmidazolium, two inhibitors of the calcium/calmodulin complex. In contrast with the calcium/calmodulin-dependent activation of constitutive NOS, the activation of inducible forms of NOS (iNOS) is regulated by transcription; once translated, the protein tightly associates with calmodulin, explaining the relative insensitivity of iNOS to modifications of the intracellular calcium concentration. However, the iNOS from human hepatocytes, or Hep-NOS, is partially inhibited by calcium chelators and by antagonists of calmodulin; furthermore, natural and recombinant Hep-NOS might differ in their sensitivity to calcium and calmodulin.

The NO synthase activated by IL-4 in unstimulated monocytes may therefore be of the constitutive type, inasmuch as an endothelial type cNOS mRNA can be detected in these cells by RT-PCR. The presence of both inducible iNOS (type II) and constitutive endothelial NOS (type III) mRNA has been recently reported in human monocytes and monocytic cell lines, such as U937. Interestingly, stimulation with IFN-γ and TNF-α led to an induction of iNOS mRNA expression, whereas cNOS mRNA was reduced in the same time. A reciprocal regulation of cNOS and iNOS mRNA has already been observed in other cell types, suggesting the control of their expression by coordinated mechanisms. In our investigation, however, we did not detect a significant reduction of cNOS mRNA following the addition of IFN-γ alone. In addition, treatment with either IL-4, or IL-4 and anti-C23, did not modify the expression of cNOS mRNA in U937 cells. In contrast, these treatments were found to induce the expression of the inducible iNOS, both at the mRNA level, as detected by RT-PCR, and at the protein level, as revealed by immunocytochemistry (Dugas et al.; manuscript in preparation and Reference 56).

Preliminary immunofluorescence experiments, using a mouse monoclonal antibody against anti-human endothelial NOS (Affinity Research Products, Nottingham, UK) confirm the existence of an endothelial type cNOS protein in monocytic cells such as U937. Experiments are in progress to determine if this protein is enzymatically active and whether it is also present in human blood monocytes. Our results also indicate that a calcium increase, by itself, is not sufficient to trigger the activation of cNOS in monocytic cells. They suggest that IL-4 provides other signals or co-factors that are required to obtain a full catalytic activity. One such co-signal could be related to tyrosine phosphorylation, inasmuch as the catalytic activity of another type of constitutive NOS, the neuronal enzyme, is impaired in the presence of tyrosine kinase inhibitors. Indeed, preliminary data suggest that IL-4-induced cGMP accumulation may be impaired by tyrosine kinase inhibitors.

These results indicate that different isoforms of NO synthase, constitutive and inducible, may be expressed in human monocytes, depending on their stage of differentiation and the combination of signals provided.

References
1. Paul WE, Ohara JB. B cell stimulatory factor-1/interleukin-4. Ann Rev Immunol 1987; 5: 429–459.
2. Te Velde AA, Klop LFG, Yard BA, De Vries JF, Figdor CG. Modulation of phenotypic and functional properties of human peripheral blood monocytes by IL-4. J Immuno1988; 140: 1546–1554.
3. Vercelli D, Jabara HH, Le BW, Woodland N, Geha RS, Leung DY. Human
recombinant interleukin-4 induces FcεRI/CD23 on normal human mono-
cytes. J Exp Med 1998; 187: 1406–1416.

4. Te Velde AA, Hultbomers JJ, De Vries JE, Figdor CG. IL-4 decreases FcyR membranous expression and Fcy-mediated cytotoxicity of human mono-
cytes. J Immunol 1997; 159: 5046–5053.

5. Wong HL, Welch GR, Brandes MI, Wahl SM. IL-4 antagonizes induction of FcγRIII (CD16) expression by transforming growth factor-β on human monocytes. J Immunol 1995; 155: 1475–1483.

6. Lauener RP, Goyert SM, Geha R, Vercelli D. Interleukin-4 down-regulates the expression of CD14 in normal human monocytes. Eur J Immunol 1990; 20: 2373–2379.

7. Schindler C, Kashleva H, Pemis A, Pine R, Rothman P. STF-IL-4: a novel IL-4-induced signal-transducing factor. EMBO J 1994; 13: 1330–1336.

8. Kolb JP, Paul-Bugeaud N, Damiai C, Yamaoka K, Draper JC, Dugas B. Interleukin-4 stimulates cGMP production by IFN-γ-activated human monocytes. Involvement of the nitric oxide synthase pathway. J Biol Chem 1994; 269: 9811–9816.

9. Mautino G, Paul-Bugeaud N, Chanez P, et al. Heterogeneous spontaneous and interleukin-4-induced nitric oxide production by human monocytes. J Leukoc Biol 1994; 56: 15–20.

10. MacDonald RJ, Smith GH, Freyhla AR, Chipetje GM. Isolation of mRNA using guanidium salts. Methods Enzymol 1987; 152: 407–419.

11. Lasfar A, Armfield C, Ballina JP, Kolb JP. Activation pathways triggered by interleukin-4 in the human plasmacytoma cell line RPMI-8226. Differences with resting B lymphocytes. J Cytokine News 1995; 4: 213–221.

12. Hart PH, Vita DS, Burgess GA, White GA, Ficovich DS, Hamilton JA. Potential anti-inflammatory effects of IL-4. Suppression of human monocyte tumor necrosis factor, interleukin-1 and prostaglandin E2. Proc Natl Acad Sci USA 1989; 86: 3808–3812.

13. de Wit H, Hendriks DW, Hatje MR, Vellenga E. Interleukin-4 receptor regu-
lation in human monocytic cells. Blood 1994; 84: 608–615.

14. Takeshita R, Asao H, Ohmori N, et al. Cloning of the γ chain of the human IL-2 receptor. Science 1992; 257: 379–382.

15. Bussmann H, Iales L, Ganesan S, Calle R, Zawalich W. Ca2+– cytosolic AMP interactions in sustained cellular responses. In: Interactions Among Cell Signalling Systems. Ciba Foundation Symposium 164. Chichester: John Wiley and Sons, 1992, 98–112.

16. Armas A, Ho JL. IL-4 receptor signal transduction in human monocytes is associated with protein kinase C translocation. J Immunol 1992; 149: 1258–1264.

17. Ho JL, Zhu B, He S, Xu D, Bothara R, Bothara R. IL-4 receptor signaling in human monocytes and 1987 cells involves the activation of a phosphatidylinositol specific: phosphatidylinositol 4-kinase C: a comparison with chemotactic peptide, FMLP, phospholipase D, and sphingomyelinase. J Exp Med 1994; 180: 1457–1469.

18. Renz H, Gong JH, Schmidt A, Nain M, Genssa D. Release of tumor necrosis factor-α from macrophages. Enhancement and suppression are dose-dependently regulated by prostaglandin E2 and cyclic nucleotides. J Immunol 1988; 141: 1880–1883.

19. Li SH, Chan SC, Toshitori A, Lesing DYM, Harflin JM. Synergistic effects of interleukin-4 and interferon-gamma on monocyte phosphodiesterase activity. J Invest Dermatol 1992; 99: 65–70.

20. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysio-
logy and pharmacology. Pharmacol Rev 1991; 43: 109–144.

21. Nathan CF. Nitric oxide as a secretory product of mammalian cells. PNAS USA 1992; 90: 395–399.

22. Nathan CF, Hilbs JB. Role of nitric oxide synthase in macrophage antitumoractivity. Current Opin in Immunol 1991; 3: 65–70.

23. Stuehr DJ, Griffith OW. Mammalian NO synthases. Adv Enzymol 1992; 65: 287–346.

24. Lowenstein C, Giant CS, Bredt DS, Snyder SH. Cloning and expression of a macrophage nitric oxide synthase cDNA. Proc Natl Acad Sci USA 1992; 89: 8711–8715.

25. Lysosizes C, Oishi FJ, Cunningham MM. Molecular cloning and functional expression of an inducible nitric oxide synthase from a murine macro-
phage cell line. J Biol Chem 1992; 267: 1877–1880.

26. Brown JO, Cai H, Galayzky J, et al. Cloning and characterization of indu-
cible nitric oxide synthase from mouse macrophages. Science 1992; 256: 220–228.

27. Geller DA, Lowenstein C, Shapiro RA, et al. Molecular cloning and expression of inducible nitric oxide synthase from human hepatocytes. Proc Natl Acad Sci USA 1992; 90: 3491–3495.

28. Endres S, Palie JH, Sichga D, et al. Cyclic nucleotides differentially regu-
late the expression of tumor necrosis factor-α and interleukin-1β by human mononuclear cells. Immunology 1991; 72: 56–60.

29. Paul-Bugeaud N, Pérez J, Bouquet JP, Dugas B. Role of cyclic nucleotides and nitric oxide in blood mononuclear cell IgF production stimulated by IL-4. J Cytokine News 1995; 7: 64–69.

30. Helling N, Ulmer AJ, Duchow M, Ernst M, Flad HD, Haushabich S. Nitric oxide synthase: mRNA expression of different isoforms in stimulated human mono-
cytes/macrophages. Eur J Immunol 1994; 24: 1941–1944.

31. Voloucoules I, Rivera-Moreno V, Dugas B, et al. The Killing of Leishma-
mann r major by human macrophages is mediated by nitric oxide induced after ligation of FcεRI/CD23 surface antigen. Proc Natl Acad Sci USA 1995. In press.

32. Rodríguez E, Quinina U, Fargni L, Laron-Cazal M, Boccardt J. Blockade of nitric oxide synthesis by tyrosine kinase inhibitors in neurons. Neuro-
pharmacology 1994; 33: 1267–1274.

ACKNOWLEDGMENTS. This work was supported by INSERM and by a grant from ARC.

Received 9 March 1995; accepted in revised form 11 May 1995

Mediators of Inflammation Vol 4 1995 305